News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis completes clinical trial with the antifibrotic agent, PXS25
Pharmaxis today announced it had completed the first Phase I clinical trial in healthy volunteers with its new drug candidate, PXS25.
Read full media release - pdf
Pharmaxis to acquire Canadian company TOPIGEN Pharmaceuticals Inc.
Pharmaxis Ltd (ASX:PXS) announced today that it has signed an agreement to acquire Canadian based private biopharmaceutical company Topigen Pharmaceuticals Inc. in a transaction that will enhance the Pharmaxis respiratory drug development portfolio and complement the existing products and drugs under development.
Read full media release - pdf
Pharmaxis receives response letter from the FDA on Aridol application
Pharmaxis today announced it had received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in relation to its New Drug Application (NDA) for Aridol™ (mannitol inhalation powder).
Read full media release - pdf